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Abstract To study the influence of a linker rigidity and
donor–acceptor properties, the P–CH2–O–CHR– fragment
in acyclic nucleoside phosphonates (e.g., acyclovir, teno-
fovir) was replaced by the P–CH2–HN–C(O)– residue. The
respective phosphonates were synthesized in good yields
by coupling the straight chain of x-aminophosphonates and
nucleobase-derived acetic acids with EDC. Based on the
1H and 13C NMR data, the unrestricted rotation within the
methylene and 1,2-ethylidene linkers in phosphonates from
series a and b was confirmed. For phosphonates containing
1,3-propylidene (series c) fragments, antiperiplanar dispo-
sition of the bulky O,O-diethylphosphonate and substituted
amidomethyl groups was established. The synthesized
ANPs P–X–HNC(O)–CH2B (X = CH2, CH2CH2, CH2-
CH2CH2, CH2OCH2CH2) appeared inactive in antiviral
assays against a wide variety of DNA and RNA viruses at
concentrations up to 100 lM while marginal antiprolifer-
ative activity (L1210 cells, IC50 = 89 ± 16 lM and HeLa
cells, IC50 = 194 ± 19 lM) was noticed for the analog
derived from (5-fluorouracyl-1-yl)acetic acid and O,O-di-
ethyl (2-aminoethoxy)methylphosphonate.
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Introduction
The search for new compounds endowed with antiviral
activity has been underway for decades. Several research
groups have been active in this field, both in academia and
pharmaceutical industry. Despite these efforts, for many
viruses efficient drugs have not been yet discovered. In
addition, anticancer drugs available so far exhibit limited
applicability. The high mutation rate observed for some
viruses makes the issue highly complex. Within medica-
tions applied to treat viral infections, acyclic nucleoside
phosphonates (ANPs) play an important role [1–3]. The
prototype of the acyclic nucleoside phosphonates (ANPs),
(S)-HPMPA (3), was never commercialized but it gave rise
to three marketed products [cidofovir (4), adefovir (1), and
tenofovir (2)] that are often prescribed by physicians. So
far known structural modifications of compounds 1–4
accomplished within a chain connecting nucleobase and
phosphonic acid moieties did not lead to discovery of
analogs having higher antiviral activity (Fig. 1).
Analysis of the mechanism of action of ANPs [3, 4]
allows to conclude that within structures of newly designed
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analogs of ANPs, the following fragments have to be
installed: (1) a phosphonate unit (P–CH2) which prevents
enzymatic hydrolysis of the P–O bond present in natural
phosphates, while being capable of further phosphoryla-
tion; (2) canonical nucleobases or their very close
structurally heterocyclic systems to assure efficient inter-
actions with the complementary nucleobases of the other
polynucleotide chain; (3) a linker to adjust a distance
between a nucleobase and a phosphorus atom which should
contain four atoms considered optimal at this moment.
Taking into account high antiviral activity of com-
pounds 1–4, one may be interested in specific interactions
of oxygen lone pairs and also of the entire phospho-
nomethoxy (P–CH2–O) fragment. The oxygen atom
located within a P–CH2–O–CHR– fragment can serve as a
lone pair donor in intermolecular interactions, and single
bonds connecting atoms in the linker ensure free rotation.
To modify interactions of atoms located in the linker it is
reasonable to consider replacing selected fragments of the
linker for another moiety.
During studies on biological activity of peptides,
replacements of the amide [–C(O)–NH–] residue for sev-
eral isosteric fragments (including a methylene ether [–
CH2–O–] moiety) are commonly applied [5–7]. This par-
ticular replacement allows to preserve steric conformity of
both bonding systems but essentially influences donor–
acceptor interactions and possibilities of a rotation around
the specific bonds within the linker [completely free around
the CH2–O bond (11.3 kJ/mol—barrier to rotation) as
compared to the hindered around the C(O)–NH bond
(88 kJ/mol—barrier to rotation)]. In general, this isosteric
replacement diminishes affinity of modified peptides in
comparison with the natural ones.
The proposed structural modification of ANPs 1–4 relies
on the incorporation of a specific fragment which will be
able to increase donor–acceptor interactions within the
linker. In our first approach, the [P–CH2–O–CHR–] frag-
ment will be replaced with the amide [P–CH2–HN–C(O)–]
residue to provide amides 5 (Scheme 1). In addition, a part
of the linker containing the amide bond becomes rigid and
thus may influence the activity of modified ANPs.
Several decades ago, a concept of phosphonate peptide
nucleic acids (PPNA) was introduced [8–11] and a variety
of related monomers 6 were synthesized, however, limited
to aminomethyl- and aminoethylphosphonate derivatives.
Our interest in the synthesis of phosphonates of general
formula 5 significantly extends structural diversity of
potential new monomers 6 primarily in the
aminoalkylphosphonate fragment.
Herein, we wish to describe our studies on the synthesis
and the biological activity of the amides 5. The synthetic
strategy involves the formation of the amide bond from the
respective acetic acid derivatives 8 and x-aminophospho-
nates 7 (Scheme 1).
Results and discussion
To synthesize the first series of the amides 5, x-
aminophosphonates 7a–7d containing straight chain linkers
were selected (Scheme 2). The x-aminophosphonates 7a–
7d were prepared according to the described procedures
[12–14]. Among them, aminomethylphosphonate 7a was
considered as the most important since it was later trans-
formed into the analogs 17a–24a in which nitrogen atoms
(N1 or N9) in nucleobases and the phosphorus atom are
separated by four bonds, thus providing compounds
structurally closest to the drugs 1–4.
Uracil (9)-, 5-fluorouracil (10)-, 5-bromouracil (11)-,
thymine (12)-, and benzouracil (14)-containing acetic acids
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are also known compounds and they were synthesized by
alkylation of the respective nucleobases by chloro- or
bromoacetic acid [15–19].
For future introduction of cytosine- and adenine-acetyl
fragments, the protected acids 13 [20] and 15 [21] had to be
prepared to significantly increase lipophilicity of the
respective amides 21a–21d and 23a–23d. (2-Amino-6-
chloropurin-9-yl)acetic acid 16 [22] served as a precursor
to guanine-decorated amides 25a–25d (Scheme 3).
A large number of coupling reagents have been devel-
oped for the efficient formation of the amide bond [23, 24]
but only some of them proved useful in the peptide
chemistry [25]. In search for the coupling system to be
applied to our tasks, we were directed by studies of acy-
lation of model secondary amines with (thymine-1-
yl)acetic acid (12) [26].
When the aminophosphonate 7a was reacted with the
acid 12 in the presence of benzotriazol-1-yloxytris
(dimethylamino)phosphonium hexafluorophosphate (BOP)
[27], (benzotriazol-1-yloxy)tripyrrolidinophosphonium
hexafluorophosphate (PyBOP) [28], N-[(dimethylamino)-
1H-1,2,3-triazolo-[4,5-b]pyridin-1-ylmethylene]-N-methyl-
methanaminium hexafluorophosphate N-oxide (HATU)
[29], and 1-[(1-(cyano-2-ethoxy-2-oxoethylideneamino-
oxy)-dimethylamino-morpholinomethylene)]methanamini-
um hexafluorophosphate (COMU) [29] with triethylamine
or diethylisopropylamine as additives, the expected amide
20a could not be isolated from the complex reaction
mixtures.
The same coupling was next performed with propy-
lphosphonic anhydride (T3P) [30] and N-(3-
dimethylaminopropyl)-N0-ethylcarbodiimide hydrochloride
(EDC) [31, 32] to produce pure amide 20a [33] in
acceptable yields (Table 1). As expected, microwave irra-
diation significantly accelerated the amide bond formation.
In most cases, couplings of the aminophosphonates 7a–7d
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with nucleobase-substituted acetic acids 9–16 in the pres-
ence of EDC proceeded almost quantitatively. However,
the final products 17a–24d were isolated in moderate
yields since several crystallizations were necessary to
remove the last traces of triethylamine hydrochloride.
The guanine-containing phosphonates 25a–25d were
prepared from the 6-chloropurine precursors 24a–24d by
hydrolysis in acidic medium (Scheme 3) [34].
Conformational analysis
We also aimed to study the conformational behavior of an
acyclic linker connecting a phosphorus atom and the amide
nitrogen for future structure–activity considerations. Free
rotation around P–CH2 and H2C–NH bonds in phospho-
nates 17a–25a, as depicted by 26a in Fig. 2, is evidenced
from the vicinal HNCH couplings of 5.9 Hz observed in
the spectra of 21a and 25a taken in chloroform-d and
DMSO-d6, respectively. In solutions in these solvents as
well as in methanol-d4 H2CP are equivalent since they
always appeared as a one doublet from two-bond HP
coupling of 11.8 Hz.
Structure 26b (Fig. 2) summarizes conformational
flexibility of phosphonates 17b–25b which is proved by the
observation of the vicinal H2C–CH2 couplings of 7.6 Hz.
Since 13C NMR spectra of phosphonates 17c–25c
showed large values (18.1–19.6 Hz) of vicinal PCCC
couplings, the antiperiplanar disposition of the P–CC–CH2
groups is proposed and represented by the Newman pro-
jection 26c.
Although significant values (11.0–12.1 Hz) were
observed in the 13C NMR spectra of phosphonates 17d–
25d for vicinal PCOC couplings, they cannot be applied
with confidence to discuss conformational behavior of the
–CH2OCH2CH2– linkage since the angular dependence
within a P–C–O–C framework has not yet been established.
Antiviral activity
All phosphonates 17–25 were evaluated for inhibitory
activity against a wide variety of DNA and RNA viruses,
using the following cell-based assays: (a) human embry-
onic lung (HEL) cells: herpes simplex virus-1 (KOS
strain), herpes simplex virus-2 (G strain), thymidine
kinase-deficient (acyclovir resistant) herpes simplex virus-
1 (TK- KOS ACVr strain), vaccinia virus, adenovirus-2,
vesicular stomatitis virus, cytomegalovirus (AD-169 strain
and Davis strain), varicella-zoster virus (TK? VZV strain
and TK- VZV strain); (b) HeLa cell cultures: vesicular
stomatitis virus, Coxsackie virus B4 and respiratory syn-
cytial virus; (c) Vero cell cultures: parainfluenza-3 virus,
reovirus-1, Sindbis virus, Coxsackie virus B4, Punta Toro
virus, yellow fever virus; (d) CrFK cell cultures: feline
corona virus (FIPV) and feline herpes virus (FHV);
(e) MDCK cell cultures: influenza A virus (H1N1 and
H3N2 subtypes) and influenza B virus. Ganciclovir, cido-
fovir, acyclovir, brivudine, zalcitabine, zanamivir,
alovudine, amantadine, rimantadine, ribavirin, dextran
sulfate (molecular weight 10,000, DS-10000), mycophe-
nolic acid, Hippeastrum hybrid agglutinin (HHA) and
Urtica dioica agglutinin (UDA) were used as the reference
compounds. The antiviral activity was expressed as the
EC50: the compound concentration required to reduce virus
plaque formation (VZV) by 50% or to reduce virus-induced
cytopathogenicity by 50% (other viruses). None of the
tested compounds showed appreciable antiviral activity
toward any of the tested DNA and RNA viruses at con-
centrations up to 100 lM, nor affected cell morphology of
HEL, HeLa, Vero, MDCL, and CrFK cells.
Cytostatic activity
The 50% cytostatic inhibitory concentration (IC50) causing
a 50% decrease in cell proliferation was determined against
Table 1 Optimization of the reaction conditions
Coupling reagent Additive Solvent Time/temp. Yield/% Procedure
T3P TEA DMF 24 h/r.t. 40 A
EDC TEA DMF 72 h/r.t. 60 B
EDC TEA CHCl3 48 h/r.t. 62 B
EDC TEA CHCl3 15 min, 1 h/35 C, 100 W 62 C
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murine leukemia L1210, human lymphocyte CEM, human
cervix carcinoma HeLa, and human dermal microvascular
endothelial cells (HMEC-1).
Among all tested compounds, only phosphonate 18d
showed slight antiproliferative activity toward L1210
(IC50 = 89 ± 16 lM) and HeLa cells (IC50 =
194 ± 19 lM) and thus enlarges a collection of 5-fluo-
rouracil derivatives which together with the parent
compound have been widely clinically applied in therapies
of various cancers [35]. Furthermore, the closest structural
analog of 18d (compound 18e) was found active in vitro
against L1210 cells at concentration of 15 lM [36]
(Fig. 3).
Conclusion
Replacement of the P–CH2–O–CHR– fragment in ANPs
(e.g., acyclovir, tenofovir) by the P–CH2–HN–C(O)–
residue was introduced to study the influence of a linker
rigidity and changes in donor–acceptor properties. To
elaborate an appropriate synthetic methodology, a series of
the 36 respective phosphonates as O,O-diethyl esters was
prepared in good yields by the EDC-induced coupling of
the straight chain x-aminophosphonates and nucleobase-
derived acetic acids. Besides the rigidity of the amide bond
based on the 1H and 13C NMR data, it was concluded that
the unrestricted rotation within the methylene (series a) and
1,2-ethylidene (series b) linkers takes place while for
phosphonates containing 1,3-propylidene (series c) frag-
ments antiperiplanar disposition of the bulky O,O-
diethylphosphonate and substituted amidomethyl groups
was observed. The phosphonates 17a–25d appeared inac-
tive in antiviral assays against a wide variety of DNA and
RNA viruses at concentrations up to 100 lM. Marginal
antiproliferative activity (L1210, IC50 = 89 ± 16 lM and
HeLa, IC50 = 194 ± 19 lM) was noticed for the phos-
phonate 18d derived from (5-fluorouracyl-1-yl)acetic acid
and O,O-diethyl (2-aminoethoxy)methylphosphonate.
Studies on the analogous phosphonates containing func-
tionalized linkages are currently ongoing in our laboratory
and the most active diethyl esters will be transformed into
the free ANP and further derivatized to selected prodrug
phosphonates [37].
Experimental
1H NMR spectra were recorded in CD3OD, CDCl3, or
DMSO-d6 on the following spectrometers: Varian Gemini
2000BB (200 MHz) and Bruker Avance III (600 MHz)
with TMS as internal standard. 13C NMR spectra were
recorder for CD3OD, CDCl3, or DMSO-d6 solution on the
Bruker Avance III at 151.0 MHz. 31P NMR spectra were
performed on the Varian Gemini 2000BB at 81.0 MHz or
on Bruker Avance III at 243.0 MHz. IR spectral data were
measured on a Bruker Alpha-T FT-IR spectrometer.
Melting points were determined on a Boetius apparatus.
Elemental analyses were performed by Microanalytical
Laboratory of this Faculty on Perkin Elmer PE 2400 CHNS
analyzer and their results were found to be in good
agreement (±0.3%) with the calculated values.
The following absorbents were used: column chro-
matography, Merck silica gel 60 (70–230 mesh); analytical
TLC, Merck TLC plastic sheets silica gel 60 F254. TLC
plates were developed in chloroform–methanol solvent
systems. Visualization of spots was effected with iodine
vapors. All solvents were purified by methods described in
the literature.
Synthesis of amides 17–24
General procedure A
A solution of 0.100 g aminophosphonate 7a (0.598 mmol)
in 2 cm3 DMF containing 0.100 g (thymine-1-yl)acetic
acid (12, 0.544 mmol) was cooled to 0 C and 0.152 cm3
TEA (1.09 mmol) followed by a 0.481 cm3 of a 50%
solution of T3P in DMF (0.816 mmol) were added. The
reaction mixture was stirred at room temperature for 24 h,
concentrated in vacuo and treated with 5 cm3 water. A
solid was filtered off, air dried, and subjected to chro-
matography on a silica gel column with chloroform–
methanol mixtures (20:1, 10:1 v/v) to give pure compound
20a (0.072 g, 40% yield) as a white powder.
General procedure B
To a solution of aminophosphonates 7a–7d (1.00 mmol) in
2 cm3 DMF or chloroform the respective acetic acids 9–16
(1.00 mmol), EDC 9 HCl (1.00 mmol), and TEA
(1.00 mmol) were added. The reaction mixture was stirred
at room temperature for 48–72 h and then concentrated in
vacuo. The residue was chromatographed on a silica gel
column with chloroform–methanol mixtures and crystal-
lized from the appropriate solvents.
N
O
H
18d
this report known compound
N
NH
O
O
F
O(EtO)2(O)P
N
O
H
18e
N
NH
O
O
F
HO
HO
HO
Fig. 3 Active derivatives of 5-fluorouracil
Acyclic nucleoside phosphonates containing the amide bond 2167
123
General procedure C
To a solution of aminophosphonates 7a–7d (1.00 mmol) in
2 cm3 chloroform the respective acetic acids 9–16
(1.00 mmol), EDC 9 HCl (1.00 mmol), and TEA
(1.00 mmol) were added. The reaction mixture was irra-
diated (100 W) at 35 C for the specified time (15 min–
3 h) and then concentrated in vacuo. The residue was
chromatographed on a silica gel column with chloroform–
methanol mixtures and crystallized from the appropriate
solvents.
Diethyl [2-(3,4-dihydro-2,4-dioxopyrimidin-1(2H)-yl)ac-
etamido]methylphosphonate (17a, C11H18N3O6P)
The crude product obtained from 0.100 g diethyl 2-
aminomethylphosphonate (7a, 0.60 mmol) and 0.097 g
(uracil-1-yl)acetic acid (9, 0.60 mmol) in the presence of
0.115 g EDC 9 HCl (0.60 mmol) and 0.083 cm3 TEA
(0.60 mmol) according to the general procedure B was
chromatographed with chloroform–methanol mixtures (50:1,
20:1 v/v) to give pure compound 17a (0.106 g, 55% yield)
as a white powder. M.p.: 215–217 C; IR (KBr): m = 3254,
3058, 2997, 2882, 2831, 1703, 1679, 1259, 1193,
1031 cm-1; 1H NMR (200 MHz, CD3OD): d = 7.56 (d,
3J = 7.9 Hz, 1H, HC6), 5.71 (d, 3J = 7.9 Hz, 1H, HC5),
4.51 (d, 3J = 1.4 Hz, 2H, C(O)CH2), 4.26–4.11 (m, 4H,
2 9 POCH2CH3), 3.78 (d,
2J = 11.8 Hz, 2H, PCH2N), 1.37
(t, J = 7.0 Hz, 6H, 2 9 POCH2CH3) ppm;
13C NMR
(151 MHz, CD3OD): d = 167.92 (d, J = 3.7 Hz), 165.38,
151.36, 146.37, 100.85, 62.79 (d, J = 6.5 Hz, POC), 49.56,
34.23 (d, J = 158.5 Hz, PC), 15.28 (d, J = 5.8 Hz, POCC)
ppm; 31P NMR (243 MHz, CD3OD): d = 23.6 ppm.
Diethyl 2-[2-(3,4-dihydro-2,4-dioxopyrimidin-1(2H)-yl)ac-
etamido]ethylphosphonate (17b, C12H20N3O6P)
The crude product obtained from 0.100 g diethyl 2-
aminoethylphosphonate (7b, 0.550 mmol) and 0.094 g
(uracil-1-yl)acetic acid (9, 0.55 mmol) in the presence of
0.105 g EDC 9 HCl (0.550 mmol) and 0.077 cm3 TEA
(0.55 mmol) according to the general procedure B was
chromatographed with chloroform–methanol mixtures
(50:1, 20:1 v/v) to give pure compound 17b (0.095 g,
52% yield) as a white powder. M.p.: 138–140 C; IR
(KBr): m = 3340, 2986, 2953, 2896, 2826, 1696, 1673,
1236, 1024 cm-1; 1H NMR (600 MHz, CD3OD): d = 7.52
(d, 3J = 7.9 Hz, 1H, HC6), 5.70 (d, 3J = 7.9 Hz, 1H,
HC5), 4.43 (s, 2H, C(O)CH2), 4.18–4.10 (m, 4H,
2 9 POCH2CH3), 3.48 (dt, J = 12.3 Hz, J = 7.6 Hz, 2H,
PCH2CH2), 2.10 (dt, J = 15.3 Hz, J = 7.6 Hz, 2H, PCH2),
1.36 (t, J = 7.1 Hz, 6H, 2 9 POCH2CH3) ppm;
13C NMR
(151 MHz, CD3OD): d = 167.92, 165.38, 151.49, 146.38,
100.95, 62.09 (d, J = 6.5 Hz, POC), 49.81, 33.41, 24.87
(d, J = 139.0 Hz, PC), 15.31 (d, J = 6.2 Hz, POCC) ppm;
31P NMR (243 MHz, CD3OD): d = 29.34 ppm.
Diethyl 3-[2-(3,4-dihydro-2,4-dioxopyrimidin-1(2H)-yl)ac-
etamido]propylphosphonate
(17c, C13H22N3O6P 9 H2O)
The crude product obtained from 0.080 g diethyl 3-
aminopropylphosphonate (7c, 0.41 mmol) and 0.070 g
(uracil-1-yl)acetic acid (9, 0.41 mmol) in the presence of
0.079 g EDC 9 HCl (0.41 mmol) and 0.057 cm3 TEA
(0.41 mmol) according to the general procedure B was
chromatographed with chloroform–methanol mixtures
(50:1, 20:1 v/v) and the selected fractions were crystal-
lized from ethyl acetate to give pure compound 17c
(0.046 g, 32% yield) as a white solid. M.p.: 120–122 C;
IR (KBr): m = 3327, 3101, 2989, 2937, 2885, 2835, 1697,
1670, 1563, 1240, 1039 cm-1; 1H NMR (200 MHz,
CD3OD): d = 7.56 (d,
3J = 7.9 Hz, 1H, HC6), 5.70 (d,
3J = 7.9 Hz, 1H, HC5), 4.45 (s, 2H, C(O)CH2), 4.28–4.03
(m, 4H, 2 9 POCH2CH3), 3.30 (t, J = 6.9 Hz, 2H,
PCH2CH2CH2), 1.95–1.68 (m, 4H, PCH2CH2), 1.36 (t,
J = 7.1 Hz, 6H, 2 9 POCH2CH3) ppm;
13C NMR
(151 MHz, CD3OD): d = 168.08, 165.41, 151.44,
146.46, 100.85, 61.90 (d, J = 6.0 Hz, POC), 50.00,
39.34 (d, J = 18.8 Hz, PCCC), 22.13 (d, J = 4.5 Hz,
PCC), 21.91 (d, J = 142.1 Hz, PC), 15.30 (d, J = 5.7 Hz,
POCC) ppm; 31P NMR (81 MHz, CD3OD):
d = 33.69 ppm.
Diethyl [2-[2-(3,4-dihydro-2,4-dioxopyrimidin-1(2H)-
yl)acetamido]ethoxy]methyl phosphonate
(17d, C13H22N3O7P)
The crude product obtained from 0.050 g diethyl (2-
aminoethoxy)methylphosphonate (7d, 0.237 mmol) and
0.040 g (uracil-1-yl)acetic acid (9, 0.237 mmol) in the
presence of 0.045 g EDC 9 HCl (0.237 mmol) and
0.033 cm3 TEA (0.237 mmol) according to the general
procedure B was chromatographed with chloroform–
methanol mixtures (50:1, 20:1 v/v) and the selected
fractions were crystallized from ethyl acetate–hexane
mixture to give pure compound 17d (0.060 g, 70% yield)
as white needles. M.p.: 116–117 C; IR (KBr): m = 3320,
3098, 2984, 2980, 2951, 2888, 2821, 1695, 1673, 1257,
1031 cm-1; 1H NMR (200 MHz, CD3OD): d = 7.56 (d,
3J = 7.9 Hz, 1H, HC6), 5.70 (d, 3J = 7.9 Hz, 1H, HC5),
4.48 (s, 2H, C(O)CH2), 4.29–4.14 (m, 4H, 2 9 POCH2-
CH3), 3.92 (d, J = 8.5 Hz, 2H, PCH2O), 3.69 (t,
J = 5.3 Hz, 2H, PCH2OCH2CH2), 3.46 (t, J = 5.3 Hz,
2H, PCH2OCH2CH2), 1.38 (t, J = 7.0 Hz, 6H,
2 9 POCH2CH3) ppm;
13C NMR (151 MHz, CD3OD):
d = 168.04, 165.39, 151.44, 146.44, 100.83, 71.44 (d,
J = 12.1 Hz, PCOC), 64.19 (d, J = 166.9 Hz, PC), 62.77
(d, J = 6.6 Hz, POC), 49.70, 38.96, 15.36 (d, J = 5.5 Hz,
POCC) ppm; 31P NMR (81 MHz, CD3OD):
d = 23.10 ppm.
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Diethyl [2-(5-fluoro-3,4-dihydro-2,4-dioxopyrimidin-
1(2H)-yl)acetamido]methylphosphonate
(18a, C11H17FN3O6P 9 0.5H2O)
The crude product obtained from 0.107 g diethyl
aminomethylphosphonate (7a, 0.640 mmol) and 0.120 g
(5-fluorouracil-1-yl)acetic acid (10, 0.640 mmol) in the
presence of 0.123 g EDC 9 HCl (0.640 mmol) and
0.089 cm3 TEA (0.64 mmol) according to the general
procedure B was filtered and crystallized from a methanol–
diethyl ether mixture to give pure compound 18a (0.127 g,
59% yield) as a white powder. M.p.: 205–208 C; IR
(KBr): m = 3224, 3061, 3000, 2941, 2830, 1738, 1700,
1034 cm-1; 1H NMR (600 MHz, CD3OD): d = 7.80 (d,
J = 6.2 Hz, 1H, HC6), 4.46 (s, 2H, C(O)CH2), 4.20–4.15
(m, 4H, 2 9 POCH2CH3), 3.76 (d, J = 11.8 Hz, 2H,
PCH2), 1.36 (t, J = 7.1 Hz, 6H, 2 9 POCH2CH3) ppm;
13C NMR (151 MHz, CD3OD): d = 167.78 (d,
3J = 3.2 Hz, C(O)NHCP), 158.54 (d, J = 26.2 Hz),
150.12, 140.17 (d, J = 232.5 Hz), 130.30 (d,
J = 34.1 Hz), 62.82 (d, J = 6.0 Hz, POC), 49.56, 34.27
(d, J = 158.6 Hz, PC), 15.28 (d, J = 5.8 Hz, POCC) ppm;
31P NMR (273 MHz, CD3OD): d = 22.71 ppm.
Diethyl 2-[2-(5-fluoro-3,4-dihydro-2,4-dioxopyrimidin-
1(2H)-yl)acetamido]ethylphosphonate
(18b, C12H19FN3O6P)
The crude product obtained from 0.114 g diethyl 2-
aminoethylphosphonate (7b, 0.629 mmol) and 0.118 g (5-
fluorouracil-1-yl)acetic acid (10, 0.629 mmol) in the pres-
ence of 0.121 g EDC 9 HCl (0.629 mmol) and 0.088 cm3
TEA (0.63 mmol) according to the general procedure B
was chromatographed with chloroform–methanol mixtures
(100:1, 50:1, 20:1 v/v) and the selected fractions were
crystallized from a methanol–diethyl ether mixture to give
pure compound 18b (0.131 g, 59% yield) as a white solid.
M.p.: 185–186 C; IR (KBr): m = 3241, 3063, 3035, 2982,
2930, 1742, 1657, 1630, 1215, 1056 cm-1; 1H NMR
(600 MHz, CD3OD): d = 7.80 (d, J = 6.2 Hz, 1H, HC6),
4.41 (s, 2H, C(O)CH2), 4.19–4.10 (m, 4H, 2 9 POCH2-
CH3), 3.51-3.46 (m, 2H, PCH2CH2), 2.13–2.08 (m, 2H, 2H,
PCH2), 1.36 (t, J = 7.1 Hz, 3H, POCH2CH3) ppm;
13C
NMR (151 MHz, CD3OD): d = 167.76, 158.53 (d,
J = 25.6 Hz), 150.19, 140.24 (d, J = 231.0 Hz), 130.27
(d, J = 34.1 Hz), 62.07 (d, J = 6.6 Hz, POC), 49.78,
33.40 (d, J = 1.6 Hz), 24.86 (d, J = 139.6 Hz, PC), 15.28
(d, J = 5.7 Hz, POCC) ppm; 31P NMR (243 MHz, CD3-
OD): d = 29.30 ppm.
Diethyl 3-[2-(5-fluoro-3,4-dihydro-2,4-dioxopyrimidin-
1(2H)-yl)acetamido]propylphosphonate
(18c, C13H21FN3O6P 9 0.5H2O)
The crude product obtained from 0.055 g diethyl 3-
aminopropylphosphonate (7c, 0.28 mmol) and 0.053 g (5-
fluorouracil-1-yl)acetic acid (10, 0.28 mmol) in the
presence of 0.054 g EDC 9 HCl (0.28 mmol) and
0.040 cm3 TEA (0.28 mmol) according to the general
procedure B was chromatographed with chloroform–
methanol mixtures (50:1, 20:1 v/v) and the selected
fractions were crystallized from a methanol–diethyl ether
mixture to give pure compound 18c (0.048 g, 47% yield)
as a white solid. M.p.: 143–144 C; IR (KBr): m = 3240,
3096, 3032, 2996, 2955, 2940, 2884, 2835, 1740, 1669,
1677, 1240, 1033 cm-1; 1H NMR (600 MHz, CD3OD):
d = 7.81 (d, J = 6.3 Hz, 1H, HC6), 4.40 (s, 2H,
C(O)CH2), 4.17–4.07 (m, 4H, 2 9 POCH2CH3), 3.33 (t,
J = 6.4 Hz, 2H, PCH2CH2CH2), 1.88–1.77 (m, 4H, PCH2-
CH2), 1.35 (t, J = 7.0 Hz, 6H, 2 9 POCH2CH3) ppm;
13C
NMR (151 MHz, CD3OD): d = 167.91, 158.58 (d,
J = 25.7 Hz), 150.18, 140.20 (d, J = 232.5 Hz), 130.40
(d, J = 33.2 Hz), 61.90 (d, J = 6.6 Hz, POC), 50.01,
39.36 (d, J = 18.7 Hz, PCCC), 22.11 (d, J = 3.9 Hz,
PCC), 21.91 (d, J = 141.9 Hz, PC), 15.32 (d, J = 5.7 Hz,
POCC) ppm; 31P NMR (243 MHz, CD3OD):
d = 32.80 ppm.
Diethyl 2-[2-(5-fluoro-3,4-dihydro-2,4-dioxopyrimidin-
1(2H)-yl)acetamido)ethoxy]methylphosphonate
(18d, C13H21FN3O7P)
The crude product obtained from 0.076 g diethyl 3-
aminopropylphosphonate (18d, 0.360 mmol) and 0.068 g
(5-fluorouracil-1-yl)acetic acid (10, 0.36 mmol) in the
presence of 0.069 g EDC 9 HCl (0.36 mmol) and
0.050 cm3 TEA (0.360 mmol) according to the general
procedure B was chromatographed with chloroform–
methanol mixtures (50:1, 20:1 v/v) and the selected
fractions were crystallized from ethyl acetate to give pure
compound 18d (0.83 g, 61% yield) as a white solid. M.p.:
69–70 C; IR (KBr): m = 3362, 3169, 3058, 2995, 2933,
2825, 1699, 1662, 1242, 1024, 974 cm-1; 1H NMR
(200 MHz, CD3OD): d = 7.83 (d, J = 6.2 Hz, 1H,
HC6), 4.44 (s, 2H, C(O)CH2), 4.29–4.14 (m, 4H,
2 9 POCH2CH3), 3.92 (d, J = 8.5 Hz, 2H, PCH2O),
3.70 (t, J = 5.3 Hz, 2H, PCH2OCH2CH2), 3.46 (t,
J = 5.3 Hz, 2H, PCOCH2CH2), 1.38 (t, J = 7.1 Hz, 6H,
2 9 POCH2CH3) ppm;
13C NMR (151 MHz, CD3OD):
d = 167.89, 158.09 (d, J = 25.7 Hz), 150.18, 140.19 (d,
J = 232.5 Hz), 130.36 (d, J = 33.2 Hz), 71.43 (d,
J = 12.1 Hz, PCOC), 64.18 (d, J = 167.6 Hz, PC), 62.79
(d, J = 6.6 Hz, POC), 49.70, 38.97, 15.36 (d, J = 5.6 Hz,
POCC) ppm; 31P NMR (81 MHz, CD3OD):
d = 23.11 ppm.
Diethyl [2-(5-bromo-3,4-dihydro-2,4-dioxopyrimidin-
1(2H)-yl)acetamido]methylphosphonate
(19a, C11H17BrN3O6P)
The crude product obtained from 0.099 g diethyl
aminomethylphosphonate (7a, 0.59 mmol) and 0.088 g,
(5-bromouracil-1-yl)acetic acid (11, 0.59 mmol) in the
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presence of 0.114 g EDC 9 HCl (0.592 mmol) and
0.083 cm3 TEA (0.59 mmol) according to the general
procedure B was chromatographed with chloroform–
methanol mixtures (50:1, 20:1 v/v) and the selected
fractions were crystallized from an ethanol–diethyl ether
mixture to give pure compound 19a (0.094 g, 40% yield)
as a white solid. M.p.: 211–213 C; IR (KBr): m = 3225,
3065, 2992, 2941, 2830, 1698, 1680, 1024, 623 cm-1; 1H
NMR (200 MHz, CD3OD): d = 8.04 (s, 1H, HC6), 4.53 (d,
J = 1.5 Hz, 2H, C(O)CH2), 4.26–4.11 (m, 4H,
2 9 POCH2CH3), 3.78 (d, J = 11.8 Hz, 2H, PCH2), 1.37
(t, J = 7.1 Hz, 6H, 2 9 POCH2CH3) ppm;
13C NMR
(151 MHz, CD3OD): d = 167.70 (d, J = 3.6 Hz), 160.72,
150.80, 145.79, 95.09, 62.83 (d, J = 6.0 Hz, POC), 49.60,
34.27 (d, J = 158.6 Hz, PC), 15.29 (d, J = 5.7 Hz, POCC)
ppm; 31P NMR (273 MHz, CD3OD): d = 22.70 ppm.
Diethyl 2-[2-(5-bromo-3,4-dihydro-2,4-dioxopyrimidin-
1(2H)-yl)acetamido]ethylphosphonate
(19b, C12H19BrN3O6P)
The crude product obtained from 0.078 g diethyl 2-
aminoethylphosphonate (7b, 0.431 mmol) and 0.107 g (5-
bromouracil-1-yl)acetic acid (11, 0.431 mmol) in the
presence of 0.083 g EDC 9 HCl (0.431 mmol) and
0.060 cm3 TEA (0.431 mmol) according to the general
procedure B was chromatographed with chloroform–
methanol mixtures (100:1, 50:1, 20:1 v/v) and the selected
fractions were crystallized from ethyl acetate to give pure
compound 19b (0.082 g, 46% yield) as white needles.
M.p.: 211–213 C; IR (KBr): m = 3224, 3164, 3067, 2994,
2822, 1708, 1680, 1216, 1019, 619 cm-1; 1H NMR
(200 MHz, CD3OD): d = 8.04 (s, 1H, HC6), 4.46 (s, 2H,
C(O)CH2), 4.24–4.07 (m, 4H, 2 9 POCH2CH3), 3.56-3.43
(m, 2H, PCH2CH2), 2.20–2.04 (m, 2H, 2H, PCH2), 1.38 (t,
J = 7.1 Hz, 3H, POCH2CH3) ppm;
13C NMR (151 MHz,
CD3OD): d = 167.68, 160.72, 150.89, 145.78, 95.17,
62.09 (d, J = 6.6 Hz, POC), 49.83, 33.43 (d,
J = 1.7 Hz), 24.86 (d, J = 139.5 Hz, PC), 15.29 (d,
J = 5.7 Hz, POCC) ppm; 31P NMR (81 MHz, CD3OD):
d = 30.20 ppm.
Diethyl 3-[2-(5-bromo-3,4-dihydro-2,4-dioxopyrimidin-
1(2H)-yl)acetamido]propylphosphonate
(19c, C13H21BrN3O6P)
The crude product obtained from 0.151 g diethyl 3-
aminopropylphosphonate (7c, 0.774 mmol) and 0.115 g
(5-bromouracil-1-yl)acetic acid (11, 0.774 mmol) in the
presence of 0.148 g EDC 9 HCl (0.774 mmol) and
0.108 cm3 TEA (0.774 mmol) according to the general
procedure B was chromatographed with dichloromethane–
methanol mixtures (100:1, 50:1, 20:1 v/v) and the selected
fractions were crystallized from a methanol–diethyl ether
mixture to give pure compound 19c (0.063 g, 20% yield)
as a white solid. M.p.: 164–166 C; IR (KBr): m = 3259,
3039, 2830, 2835, 1720, 1681, 1235, 1033 cm-1; 1H NMR
(600 MHz, CD3OD): d = 8.05 (s, 1H, HC6), 4.46 (s, 2H,
C(O)CH2), 4.21–4.04 (m, 4H, 2 9 POCH2CH3), 3.33 (t,
J = 6.4 Hz, 2H, PCH2CH2CH2), 1.98–1.72 (m, 4H, PCH2-
CH2), 1.36 (t, J = 7.0 Hz, 6H, 2 9 POCH2CH3) ppm;
13C
NMR (151 MHz, CD3OD): d = 167.84, 160.77, 150.87,
145.88, 95.09, 61.89 (d, J = 6.6 Hz, POC), 50.05, 39.36
(d, J = 18.7 Hz, PCCC), 22.09 (d, J = 4.7 Hz, PCC),
21.90 (d, J = 141.9 Hz, PC), 15.30 (d, J = 7.6 Hz, POCC)
ppm; 31P NMR (81 MHz, CD3OD): d = 33.70 ppm.
Diethyl 2-[2-(5-bromo-3,4-dihydro-2,4-dioxopyrimidin-
1(2H)-yl)acetamido)ethoxy]methylphosphonate
(19d, C13H21BrN3O7P)
The crude product obtained from 0.170 g diethyl (2-
aminoethoxy)methylphosphonate (7d, 0.805 mmol) and
0.200 g (5-bromouracil-1-yl)acetic acid (11, 0.805 mmol)
in the presence of 0.154 g EDC 9 HCl (0.805 mmol) and
0.112 cm3 TEA (0.805 mmol) according to the general
procedure C for 1.0 h was chromatographed with chloro-
form–methanol mixtures (50:1, 20:1 v/v) and the selected
fractions were crystallized from ethyl acetate to give pure
compound 19d (0.172 g, 48% yield) as a white powder.
M.p.: 149–151 C; IR (KBr): m = 3323, 3107, 2990, 2867,
2820, 2768, 1711, 1669, 1237, 1034, 972 cm-1; 1H NMR
(200 MHz, CD3OD): d = 8.04 (s, 1H, HC6), 4.49 (s, 2H,
C(O)CH2), 4.29–4.14 (m, 4H, 2 9 POCH2CH3), 3.92 (d,
J = 8.5 Hz, 2H, PCH2O), 3.69 (t, J = 5.3 Hz, 2H, PCH2-
OCH2CH2), 3.46 (t, J = 5.3 Hz, 2H, PCOCH2CH2), 1.38
(t, J = 7.1 Hz, 6H, 2 9 POCH2CH3) ppm;
13C NMR
(151 MHz, CD3OD): d = 167.82, 160.77, 150.88, 145.90,
95.06, 71.44 (d, J = 12.0 Hz, PCOC), 64.19 (d,
J = 167.6 Hz, PC), 62.80 (d, J = 6.6 Hz, POC), 49.77,
39.00, 15.40 (d, J = 5.6 Hz, POCC) ppm; 31P NMR
(81 MHz, CD3OD): d = 23.11 ppm.
Diethyl [2-(3,4-dihydro-5-methyl-2,4-dioxopyrimidin-
1(2H)-yl)acetamido]methylphosphonate
(20a, C13H22N3O6P)
The crude product obtained from 0.048 g diethyl
aminomethylphosphonate (7a, 0.287 mmol) and 0.053 g
(thymine-1-yl)acetic acid (12, 0.287 mmol) in the presence
of 0.055 g EDC 9 HCl (0.287 mmol) and 0.040 cm3 TEA
(0.287 mmol) according to the general procedure C was
chromatographed with chloroform–methanol mixtures
(50:1, 20:1 v/v) to give pure compound 20a (0.060 g,
63% yield) as a white powder. M.p.: 211.5–212.5 C; IR
(KBr): m = 3227, 3058, 2986, 2932, 2833, 1697, 1653,
1242, 1200, 1020 cm-1; 1H NMR (200 MHz, CD3OD):
d = 7.41 (q, 4J = 1.2 Hz, 1H, HC6), 4.48 (d, J = 1.5 Hz,
2H, C(O)CH2), 4.28–4.11 (m, 4H, 2 9 POCH2CH3), 3.77
(d, J = 11.8 Hz, 2H, PCH2), 1.91 (d,
4J = 1.2 Hz, 3H,
CH3), 1.37 (t, J = 6.8 Hz, 6H, 2 9 POCH2CH3) ppm;
13C
NMR (151 MHz, CD3OD): d = 168.11 (d,
3J = 4.2 Hz,
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C(O)NHCP), 165.58, 151.57, 142.15, 109.66, 62.80 (d,
J = 6.5 Hz, POC), 49.39, 34.23 (d, J = 158.5 Hz, PC),
15.28 (d, J = 5.7 Hz, POCC), 10.78 ppm; 31P NMR
(81 MHz, CD3OD): d = 23.6 ppm.
Diethyl 2-[2-(3,4-dihydro-5-methyl-2,4-dioxopyrimidin-
1(2H)-yl)acetamido]ethylphosphonate
(20b, C13H22N3O6P)
The crude product obtained from 0.100 g diethyl 2-
aminoethylphosphonate (7b, 0.550 mmol) and 0.101 g
(thymine-1-yl)acetic acid (12, 0.550 mmol) in the presence
of 0.105 g EDC 9 HCl (0.550 mmol) and 0.077 cm3 TEA
(0.55 mmol) according to the general procedure B was
chromatographed with chloroform–methanol mixtures
(100:1, 50:1, 20:1 v/v) to give pure compound 20b
(0.141 g, 74% yield) as a white powder. M.p.: 196–
197 C; IR (KBr): m = 3229, 3161, 3035, 2979, 2930,
2827, 1695, 1651, 1230, 1022 cm-1; 1H NMR (600 MHz,
CD3OD): d = 7.35 (s, 1H, HC6), 4.37 (s, 2H, C(O)CH2),
4.16–4.07 (m, 4H, 2 9 POCH2CH3), 3.45 (dt,
J = 12.2 Hz, J = 7.6 Hz, 2H, PCH2CH2), 2.07 (dt,
J = 18.2 Hz, J = 7.6 Hz, 2H, PCH2), 1.88 (s, 3H, CH3),
1.34 (t, J = 7.1 Hz, 6H, 2 9 POCH2CH3) ppm;
13C NMR
(151 MHz, CD3OD): d = 168.10, 165.57, 151.65, 142.24,
109.71, 62.10 (d, J = 6.5 Hz, POC), 49.68, 33.39 (d,
J = 1.5 Hz), 24.88 (d, J = 138.9 Hz, PC), 15.34 (d,
J = 6.0 Hz, POCC), 10.82 ppm; 31P NMR (243 MHz,
CD3OD): d = 33.29 ppm.
Diethyl 3-[2-(3,4-dihydro-5-methyl-2,4-dioxopyrimidin-
1(2H)-yl)acetamido]propylphosphonate
(20c, C14H24N3O6P 9 0.5H2O)
The crude product obtained from 0.050 g diethyl 3-
aminopropylphosphonate (7c, 0.26 mmol) and 0.047 g
(thymine-1-yl)acetic acid (12, 0.26 mmol) in the presence
of 0.049 g EDC 9 HCl (0.26 mmol) and 0.036 cm3 TEA
(0.26 mmol) according to the general procedure B was
chromatographed with chloroform–methanol mixtures
(50:1, 20:1 v/v) and the selected fractions were crystallized
from a methanol–diethyl ether mixture to give pure
compound 20c (0.043 g, 46% yield) as a white solid.
M.p.: 183–184 C; IR (KBr): m = 3264, 3158, 3093, 3035,
2982, 2944, 2884, 2830, 1698, 1683, 1238, 1016 cm-1; 1H
NMR (600 MHz, CD3OD): d = 7.38 (q, J = 1.3 Hz, 1H,
HC6), 4.40 (s, 2H, C(O)CH2), 4.16–4.07 (m, 4H,
2 9 POCH2CH3), 3.30 (t, J = 6.9 Hz, 2H, PCH2CH2-
CH2), 1.90 (d, J = 1.3 Hz, 3H, CH3), 1.88–1.77 (m, 4H,
PCH2CH2), 1.35 (t, J = 7.1 Hz, 6H, 2 9 POCH2CH3)
ppm; 13C NMR (151 MHz, CD3OD): d = 168.26, 165.61,
151.62, 142.25, 109.65, 61.87 (d, J = 6.6 Hz, POC),
49.84, 39.34 (d, J = 18.1 Hz, PCCC), 22.13 (d,
J = 4.7 Hz, PCC), 21.92 (d, J = 141.9 Hz, PC), 15.30
(d, J = 6.2 Hz, POCC), 10.78 ppm; 31P NMR (243 MHz,
CD3OD): d = 32.78 ppm.
Diethyl 2-[2-(3,4-dihydro-5-methyl-2,4-dioxopyrimidin-
1(2H)-yl)acetamido)ethoxy]methylphosphonate
(20d, C14H24N3O7P)
The crude product obtained from 0.072 g diethyl (2-
aminoethoxy)methylphosphonate (7d, 0.34 mmol) and
0.063 g (thymine-1-yl)acetic acid (12, 0.34 mmol) in the
presence of 0.065 g EDC 9 HCl (0.34 mmol) and
0.048 cm3 TEA (0.34 mmol) according to the general
procedure B was chromatographed with chloroform–
methanol mixtures (50:1, 20:1 v/v) and the selected
fractions were crystallized from ethyl acetate to give pure
compound 20d (0.060 g, 47% yield) as a white solid. M.p.:
116–117 C; IR (KBr): m = 3323, 3151, 3078, 3057, 2982,
2954, 2906, 2837, 1678, 1661, 1236, 1026 cm-1; 1H NMR
(200 MHz, CD3OD): d = 7.40 (q, J = 1.1 Hz, 1H, HC6),
4.44 (s, 2H, C(O)CH2), 4.29–4.14 (m, 4H, 2 9 POCH2-
CH3), 3.93 (d, J = 8.5 Hz, 2H, PCH2O), 3.69 (t,
J = 5.3 Hz, 2H, PCH2OCH2CH2), 3.46 (t, J = 5.3 Hz,
2H, PCOCH2CH2), 1.92 (d, J = 1.1 Hz, 3H, CH3), 1.38 (t,
J = 7.0 Hz, 6H, 2 9 POCH2CH3) ppm;
13C NMR
(151 MHz, CD3OD): d = 168.23, 165.60, 151.62,
142.26, 109.62, 71.45 (d, J = 12.1 Hz, PCOC), 64.17 (d,
J = 167.6 Hz, PC), 62.78 (d, J = 6.7 Hz, POC), 49.54,
38.98, 15.37 (d, J = 5.6 Hz, POCC), 10.79 ppm; 31P NMR
(81 MHz, CD3OD): d = 23.10 ppm.
Diethyl [2-[4-[[(benzyloxy)carbonyl]amino]-2-oxopyrim-
idin-1(2H)-yl]acetamido]methylphosphonate
(21a, C19H25N4O7P 9 0.5H2O)
The crude product obtained from 0.104 g diethyl
aminomethylphosphonate (7a, 0.622 mmol) and 0.189 g
[N4-[(benzyloxy)carbonyl]cytosine-1-yl]acetic acid (13,
0.622 mmol) in the presence of 0.119 g EDC 9 HCl
(0.622 mmol) and 0.087 cm3 TEA (0.62 mmol) according
to the general procedure B was chromatographed with
chloroform–methanol mixtures (100:1, 50:1, 20:1 v/v) and
the selected fractions were crystallized from a methanol–
petroleum ether mixture to give pure compound 21a
(0.125 g, 44% yield) as a white solid. M.p.: 180–182 C;
IR (KBr): m = 3279, 3147, 3081, 2990, 2949, 2928, 1753,
1657, 1257, 1205, 1025 cm-1; 1H NMR (600 MHz,
CDCl3): d = 9.18 (brs, 1H, HNCbz), 8.29 (brt,
J = 5.9 Hz, 1H, HNC(O)), 7.66 (d, J = 7.1 Hz, 1H,
HC6), 7.41–7.29 (m, 5H), 7.25 (brs, 1H), 5.22 (s, 2H,
CH2C6H5), 4.65 (s, 2H, C(O)CH2), 4.12–4.07 (m, 4H,
2 9 POCH2CH3), 3.75 (dd, J = 11.8 Hz, J = 5.9 Hz, 2H,
PCH2), 1.28 (t, J = 7.0 Hz, 6H, 2 9 POCH2CH3) ppm;
13C NMR (151 MHz, CDCl3): d = 166.89 (d,
J = 4.6 Hz), 163.24, 156.18, 152.72, 149.37, 135.32,
128.61, 128.50, 128.19, 95.55, 67.70, 62.78 (d,
J = 6.6 Hz, POC), 52.31, 35.07 (d, J = 157.5 Hz, PC),
16.34 (d, J = 5.6 Hz, POCC) ppm; 31P NMR (273 MHz,
CDCl3): d = 22.49 ppm.
Acyclic nucleoside phosphonates containing the amide bond 2171
123
Diethyl 2-[2-[4-[[(benzyloxy)carbonyl]amino]-2-oxopy-
rimidin-1(2H)-yl]acetamido]ethylphosphonate
(21b, C20H27N4O7P)
The crude product obtained from 0.111 g diethyl 2-
aminoethylphosphonate (7b, 0.613 mmol) and 0.186 g
[N4-[(benzyloxy)carbonyl]cytosine-1-yl]acetic acid (13,
0.613 mmol) in the presence of 0.117 g EDC 9 HCl
(0.613 mmol) and 0.085 cm3 TEA (0.61 mmol) according
to the general procedure B was chromatographed with
chloroform–methanol mixtures (100:1, 50:1, 20:1 v/v) to
give pure compound 21b (0.224 g, 78% yield) as a white
solid. M.p.: 127–128 C; IR (KBr): m = 3241, 3063, 3035,
2982, 2930, 1742, 1657, 1630, 1215, 1056 cm-1; 1H NMR
(600 MHz, CD3OD): d = 7.92 (d, J = 7.3 Hz, 1H, HC6),
7.44–7.33 (m, 5H), 7.30 (d, J = 7.3 Hz, 1H, HC5), 5.25 (s,
2H, CH2C6H5), 4.56 (s, 2H, C(O)CH2), 4.18–4.08 (m, 4H,
2 9 POCH2CH3), 3.48 (dt, J = 11.7 Hz, J = 7.6 Hz, 2H,
PCH2CH2), 2.11 (dt, J = 18.2 Hz, J = 7.6 Hz, 2H, PCH2),
1.35 (t, J = 7.1 Hz, 6H, 2 9 POCH2CH3) ppm;
13C NMR
(151 MHz, CD3OD): d = 167.65, 164.11, 157.08, 153.17,
150.21, 135.80, 128.23, 128.06, 127.89, 95.39, 67.21,
62.08 (d, J = 6.5 Hz, POC), 51.96, 33.47, 24.89 (d,
J = 139.5 Hz, PC), 15.34 (d, J = 5.6 Hz, POCC) ppm;
31P NMR (243 MHz, CD3OD): d = 29.35 ppm.
Diethyl 3-[2-[4-[[(benzyloxy)carbonyl]amino]-2-oxopy-
rimidin-1(2H)-yl]acetamido]propylphosphonate
(21c, C21H29N4O7P)
The crude product obtained from 0.050 g diethyl 3-
aminopropylphosphonate (7c, 0.26 mmol) and 0.078 g
[N4-[(benzyloxy)carbonyl]cytosine-1-yl]acetic acid (13,
0.26 mmol) in the presence of 0.049 g EDC 9 HCl
(0.26 mmol) and 0.036 cm3 TEA (0.26 mmol) according
to the general procedure B was chromatographed with
chloroform–methanol mixtures (50:1, 20:1 v/v) and the
selected fractions were crystallized from an ethyl acetate–
hexane mixture to give pure compound 21c (0.066 g, 54%
yield) as white needles. M.p.: 150–151 C; IR (KBr):
m = 3281, 3239, 3149, 3089, 3038, 2976, 2939, 1749,
1687, 1653, 1225, 1021 cm-1; 1H NMR (600 MHz,
CD3OD): d = 7.93 (d, J = 7.3 Hz, 1H, HC6), 7.45–7.35
(m, 5H), 7.31 (d, J = 7.3 Hz, 1H, HC5), 5.25 (s, 2H,
CH2C6H5), 4.56 (s, 2H, C(O)CH2), 4.16–4.07 (m, 4H,
2 9 POCH2CH3), 3.32 (t, J = 6.5 Hz, 2H, PCH2CH2-
CH2), 1.90–1.78 (m, 4H, PCH2CH2), 1.34 (t, J = 7.1 Hz,
6H, 2 9 POCH2CH3) ppm;
13C NMR (151 MHz, CD3-
OD): d = 167.79, 163.99, 157.04, 153.17, 150.28, 135.82,
128.23, 128.06, 127.89, 95.31, 67.20, 61.88 (d, J = 6.6 Hz,
POC), 52.08, 39.43 (d, J = 18.7 Hz, PCCC), 22.12 (d,
J = 4.9 Hz, PCC), 21.95 (d, J = 141.9 Hz, PC), 15.36 (d,
J = 5.9 Hz, POCC) ppm; 31P NMR (243 MHz, CD3OD):
d = 32.77 ppm.
Diethyl 2-[2-[4-[[(benzyloxy)carbonyl]amino]-2-oxopy-
rimidin-1(2H)-yl]acetamido] ethoxy]methylphosphonate
(21d, C21H29N4O8P)
The crude product obtained from 0.068 g diethyl (2-
aminoethoxy)methylphosphonate (7d, 0.32 mmol) and
0.098 g [N4-[(benzyloxy)carbonyl]cytosine-1-yl]acetic
acid (13, 0.32 mmol) in the presence of 0.062 g
EDC 9 HCl (0.32 mmol) and 0.045 cm3 TEA
(0.32 mmol) according to the general procedure B was
chromatographed with chloroform–methanol mixtures
(50:1, 20:1 v/v) and the selected fractions were crystallized
from an ethyl acetate–hexane mixture to give pure
compound 21d (0.073 g, 48% yield) as a white solid.
M.p.: 129–131 C; IR (KBr): m = 3332, 3145, 3069, 3032,
2981, 2930, 2869, 1751, 1658, 1214, 1022 cm-1; 1H NMR
(200 MHz, CD3OD): d = 7.96 (d, J = 7.4 Hz, 1H, HC6),
7.50–7.34 (m, 5H), 7.34 (d, J = 7.4 Hz, 1H, HC5), 5.27 (s,
2H, CH2C6H5), 4.61 (s, 2H, C(O)CH2), 4.28–4.14 (m, 4H,
2 9 POCH2CH3), 3.93 (d, J = 8.5 Hz, 2H, PCH2O), 3.69
(t, J = 5.3 Hz, 2H, PCH2OCH2CH2), 3.46 (t, J = 5.3 Hz,
2H, PCOCH2CH2), 1.38 (t, J = 7.0 Hz, 6H, 2 9 POCH2-
CH3) ppm;
13C NMR (151 MHz, CD3OD): d = 167.77,
163.97, 157.06, 153.17, 150.26, 135.82, 128.23, 128.06,
127.89, 95.29, 71.48 (d, J = 12.0 Hz, PCOC), 67.21, 64.21
(d, J = 166.1 Hz, PC), 62.79 (d, J = 6.6 Hz, POC), 51.82,
39.00, 15.41 (d, J = 5.8 Hz, POCC) ppm; 31P NMR
(81 MHz, CD3OD): d = 23.10 ppm.
Diethyl [2-(3,4-dihydro-2,4-dioxoquinazolin-1(2H)-yl)ac-
etamido]methylphosphonate
(22a, C15H20N3O6P 9 2H2O)
The crude product obtained from 0.058 g diethyl
aminomethylphosphonate (7a, 0.35 mmol) and 0.076 g 2-
(3,4-dihydro-2,4-dioxoquinazolin-1-yl)acetic acid (14,
0.35 mmol) in the presence of 0.067 g EDC 9 HCl
(0.35 mmol) and 0.048 cm3 TEA (0.35 mmol) according
to the general procedure C was chromatographed with
chloroform–methanol mixtures (50:1, 20:1 v/v) and the
selected fractions were crystallized from a methanol–diethyl
ether mixture to give pure compound 22a (0.086 g, 67%
yield) as a white powder. M.p.: 203–205 C; IR (KBr):
m = 3462, 3264, 3197, 2975, 2909, 1736, 1638, 1044,
1013 cm-1; 1H NMR (200 MHz, CD3OD): d = 8.10–8.05
(m, 1H), 7.75–7.66 (m, 1H), 7.32-7.21 (m, 2H), 4.76 (d,
J = 1.6 Hz, 2H, C(O)CH2), 4.27–4.12 (m, 4H, 2 9 POCH2-
CH3), 3.78 (d, J = 11.8 Hz, 2H, PCH2), 1.37 (t, J = 6.8 Hz,
6H, 2 9 POCH2CH3) ppm;
13C NMR (151 MHz, CD3OD):
d = 166.47 (d, J = 4.0 Hz, C(O)NHCP), 162.72, 150.78,
139.58, 135.05, 127.50, 122.72, 114.90, 113.99, 62.86 (d,
J = 6.6 Hz, POC), 42.31, 34.23 (d, J = 158.4 Hz, PC),
15.30 (d, J = 5.6 Hz, POCC) ppm; 31P NMR (81 MHz,
CD3OD): d = 23.56 ppm.
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Diethyl 2-[2-(3,4-dihydro-2,4-dioxoquinazolin-1(2H)-
yl)acetamido]ethylphosphonate (22b, C16H22N3O6P)
The crude product obtained from 0.051 g diethyl 2-
aminoethylphosphonate (7b, 0.28 mmol) and 0.062 g 2-
(3,4-dihydro-2,4-dioxoquinazolin-1-yl)acetic acid (14,
0.28 mmol) in the presence of 0.054 g EDC 9 HCl
(0.28 mmol) and 0.039 cm3 TEA (0.28 mmol) according
to the general procedure C was chromatographed with
chloroform–methanol mixtures (100:1, 50:1, 20:1 v/v) to
give pure compound 22b (0.073 g, 68% yield) as a white
powder. M.p.: 180–182 C; IR (KBr): m = 3249, 3205,
3083, 2983, 2930, 2882, 1736, 1637, 1027 cm-1; 1H NMR
(600 MHz, CD3OD): d = 8.64 (dd, J = 7.1 Hz,
J = 1.3 Hz, 1H), 7.69 (dt, 1H, J = 7.1 Hz, J = 1.0 Hz),
7.27 (dt, J = 8.2 Hz, J = 1.0 Hz, 1H), 7.22 (d, J = 8.2 Hz,
1H), 4.69 (s, 2H, C(O)CH2), 4.19–4.09 (m, 4H, 2 9 POCH2-
CH3), 3.50–3.46 (m, 2H, PCH2CH2), 2.14–2.08 (m, 2H,
PCH2), 1.36 (t, J = 7.1 Hz, 6H, 2 9 POCH2CH3) ppm;
13C
NMR (151 MHz, CD3OD): d = 168.55, 162.76, 150.80,
139.55, 135.04, 127.50, 122.73, 114.90, 113.99, 62.06 (d,
J = 6.6 Hz, POC), 42.55 (PCC), 33.40, 26.64, 24.91 (d,
J = 138.9 Hz, PC), 15.32 (d, J = 6.0 Hz, POCC) ppm; 31P
NMR (243 MHz, CD3OD): d = 29.51 ppm.
Diethyl 3-[2-(3,4-dihydro-2,4-dioxoquinazolin-1(2H)-
yl)acetamido]propylphosphonate (22c, C17H24N3O6P)
The crude product obtained from 0.085 g diethyl 3-
aminopropylphosphonate (7c, 0.435 mmol) and 0.096 g
2-(3,4-dihydro-2,4-dioxoquinazolin-1-yl)acetic acid (14,
0.435 mmol) in the presence of 0.083 g EDC 9 HCl
(0.435 mmol) and 0.061 cm3 TEA (0.435 mmol) accord-
ing to the general procedure B was chromatographed with
chloroform–methanol mixtures (50:1, 20:1 v/v) to give
pure compound 22c (0.083 g, 48% yield) as a white
powder. M.p.: 168–169 C; IR (KBr): m = 3267, 3201,
3148, 3065, 2984, 2928, 1736, 1661, 1638, 1232,
1031 cm-1; 1H NMR (200 MHz, CD3OD):
d = 8.07–8.02 (m, 1H), 7.73–7.64 (m, 1H), 7.30–7.17
(m, 2H), 4.70 (s, 2H, C(O)CH2), 4.23–4.05 (m, 4H,
2 9 POCH2CH3), 3.33 (t, J = 6.5 Hz, 2H, PCH2CH2-
CH2), 1.98–1.67 (m, 4H, PCH2CH2), 1.36 (t, J = 7.1 Hz,
6H, 2 9 POCH2CH3) ppm;
13C NMR (151 MHz, CD3-
OD): d = 168.74, 162.82, 150.84, 139.61, 135.01, 127.50,
122.68, 114.88, 114.07, 61.86 (d, J = 6.6 Hz, POC),
42.60, 39.24 (d, J = 19.0 Hz, PCCC), 22.17 (d,
J = 4.5 Hz, PCC), 21.85 (d, J = 141.9 Hz, PC), 15.30
(d, J = 6.3 Hz, POCC) ppm; 31P NMR (81 MHz, CD3-
OD): d = 33.86 ppm.
Diethyl 2-[2-(3,4-dihydro-2,4-dioxoquinazolin-1(2H)-
yl)acetamido]ethoxy]methylphosphonate
(22d, C17H24N3O7P)
The crude product obtained from 0.078 g diethyl (2-
aminoethoxy)methylphosphonate (7d, 0.37 mmol) and
0.061 g 2-(3,4-dihydro-2,4-dioxoquinazolin-1-yl)acetic
acid (14, 0.37 mmol) in the presence of 0.071 g
EDC 9 HCl (0.37 mmol) and 0.051 cm3 TEA
(0.37 mmol) according to the general procedure C was
chromatographed with chloroform–methanol mixtures
(50:1, 20:1 v/v) to give pure compound 22d (0.127 g,
83% yield) as a white solid. M.p.: 169–170 C; IR (KBr):
m = 3196, 3148, 3123, 3065, 2978, 2940, 1737, 1639,
1240, 1028 cm-1; 1H NMR (200 MHz, CD3OD):
d = 8.09–8.04 (m, 1H), 7.74-7.66 (m, 1H), 7.32–7.21 (m,
2H), 4.72 (s, 2H, C(O)CH2), 4.29–4.14 (m, 4H,
2 9 POCH2CH3), 3.94 (d, J = 8.5 Hz, 2H, PCH2O),
3.70 (t, J = 5.3 Hz, 2H, PCH2OCH2CH2), 3.46 (t,
J = 5.3 Hz, 2H, PCOCH2CH2), 1.38 (t, J = 7.0 Hz, 3H,
POCH2CH3) ppm;
13C NMR (151 MHz, CD3OD):
d = 168.64, 162.78, 150.82, 139.58, 135.00, 127.50,
122.69, 114.89, 114.04, 71.55 (d, J = 12.1 Hz, PCOC),
64.25 (d, J = 166.3 Hz, PC), 62.84 (d, J = 6.6 Hz, POC),
42.47, 39.00, 15.39 (d, J = 5.6 Hz, POCC) ppm; 31P NMR
(81 MHz, CD3OD): d = 23.08 ppm.
Diethyl [2-[6-(bis(tert-butoxycarbonyl))amino-9H-purin-9-
yl]acetamido]methylphosphonate (23a, C22H35N6O8P)
The crude product obtained from 0.109 g diethyl
aminomethylphosphonate (7a, 0.622 mmol) and 0.256 g
2-[6-[bis(tert-butoxycarbonyl)amino]-9H-purin-9-yl]acetic
acid (15, 0.622 mmol) in the presence of 0.125 g
EDC 9 HCl (0.622 mmol) and 0.091 cm3 TEA
(0.62 mmol) according to the general procedure B was
chromatographed with chloroform–methanol mixtures
(100:1, 50:1, 20:1 v/v) and the selected fractions were
crystallized from a methanol–petroleum ether mixture to
give pure compound 23a (0.183 g, 52% yield) as a white
solid. M.p.: 128–130 C; IR (KBr): m = 3256, 3109, 2980,
2934, 1735, 1699, 1672, 1049 cm-1; 1H NMR (600 MHz,
CD3OD): d = 8.85 (s, 1H), 8.54 (s, 1H), 5.19 (s, 2H,
C(O)CH2), 4.19–4.14 (m, 4H, 2 9 POCH2CH3), 3.78 (d,
J = 11.8 Hz, 2H, PCH2), 1.41 (s, 18H, 6 9 CH3), 1.33 (t,
J = 7.0 Hz, 6H, 2 9 POCH2CH3) ppm;
13C NMR
(151 MHz, CD3OD): d = 166.75 (d, J = 4.4 Hz,
C(O)NHCP), 153.84, 151.66, 150.14, 149.47, 147.72,
128.37, 83.91, 62.81 (d, J = 6.5 Hz, POC), 45.14, 34.41
(d, J = 158.6 Hz, PC), 26.65, 15.36 (d, J = 5.7 Hz,
POCC) ppm; 31P NMR (243 MHz, CD3OD):
d = 22.68 ppm.
Diethyl 2-[2-[6-(bis(tert-butoxycarbonyl))amino-9H-purin-
9-yl]acetamido]ethylphosphonate
(23b, C23H37N6O8P 9 0.5 H2O)
The crude product obtained from 0.108 g diethyl 2-
aminoethylphosphonate (7b, 0.596 mmol) and 0.235 g 2-
[6-[bis(tert-butoxycarbonyl)amino]-9H-purin-9-yl]acetic
acid (15, 0.596 mmol) in the presence of 0.114 g
EDC 9 HCl (0.596 mmol) and 0.083 cm3 TEA
Acyclic nucleoside phosphonates containing the amide bond 2173
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(0.60 mmol) according to the general procedure B was
chromatographed with chloroform–methanol mixtures
(100:1, 50:1, 20:1 v/v) to give pure compound 23b
(0.155 g, 47% yield) as a colorless oil. IR (film):
m = 3356, 3284, 3085, 2983, 2936, 1788, 1760, 1697,
1251, 1027 cm-1; 1H NMR (200 MHz, CD3OD): d = 8.87
(s, 1H), 8.56 (s, 1H), 5.14 (s, 2H, C(O)CH2), 4.25–4.07 (m,
4H, 2 9 POCH2CH3), 3.60–3.48 (m, 2H, PCH2CH2),
2.22–2.06 (m, 2H, 2H, PCH2), 1.43 (s, 18H, 6 9 CH3),
1.37 (t, J = 7.1 Hz, 6H, 2 9 POCH2CH3) ppm;
13C NMR
(151 MHz, CD3OD): d = 166.73, 153.85, 151.65, 150.17,
149.46, 147.72, 128.37, 83.91, 62.08 (d, J = 6.6 Hz,
POC), 45.26, 33.57, 26.64, 24.89 (d, J = 138.9 Hz, PC),
15.37 (d, J = 5.7 Hz, POCC) ppm; 31P NMR (81 MHz,
CD3OD): d = 30.17 ppm.
Diethyl 3-[2-[6-(bis(tert-butoxycarbonyl))amino-9H-purin-
9-yl]acetamido]propylphosphonate
(23c, C24H39N6O8P 9 0.5H2O)
The crude product obtained from 0.059 g diethyl 3-
aminopropylphosphonate (15, 0.30 mmol) and 0.119 g 2-
[6-[bis(tert-butoxycarbonyl)amino]-9H-purin-9-yl]acetic
acid (15, 0.302 mmol) in the presence of 0.058 g
EDC 9 HCl (0.30 mmol) and 0.042 cm3 TEA
(0.30 mmol) according to the general procedure B was
chromatographed with chloroform–methanol mixtures
(100:1 v/v) to give pure compound 23c (0.072 g, 42%
yield) as an yellowish oil. IR (film): m = 3363, 3281, 3087,
2983, 2937, 1788, 1693, 1220, 1024 cm-1; 1H NMR
(600 MHz, CD3OD): d = 8.85 (s, 1H), 8.53 (s, 1H), 5.12
(s, 2H, C(O)CH2), 4.17–4.07 (m, 4H, 2 9 POCH2CH3),
3.36 (t, J = 6.5 Hz, 2H, PCH2CH2CH2), 1.92–1.78 (m, 4H,
PCH2CH2), 1.42 (s, 18H, 6 9 CH3), 1.34 (t, J = 7.0 Hz,
6H, 2 9 POCH2CH3) ppm;
13C NMR (151 MHz, CD3-
OD): d = 166.90, 153.82, 151.65, 150.16, 149.46, 147.73,
128.43, 83.92, 61.88 (d, J = 6.6 Hz, POC), 45.42, 39.50
(d, J = 19.6 Hz, PCCC), 26.61, 22.14 (d, J = 4.6 Hz,
PCC), 22.00 (d, J = 142.6 Hz, PC), 15.33 (d, J = 5.6 Hz,
POCC) ppm; 31P NMR (243 MHz, CD3OD):
d = 32.68 ppm.
Diethyl 2-[2-[6-(bis(tert-butoxycarbonyl))amino-9H-purin-
9-yl]acetamido]ethoxy)methyl)phosphonate
(23d, C24H39N6O9P 9 0.5H2O)
The crude product obtained from 0.070 g diethyl (2-
aminoethoxy)methylphosphonate (7d, 0.33 mmol) and
0.130 g 2-[6-[bis(tert-butoxycarbonyl)amino]-9H-purin-9-
yl]acetic acid (15, 0.33 mmol) in the presence of 0.064 g
EDC 9 HCl (0.33 mmol) and 0.046 cm3 TEA
(0.33 mmol) according to the general procedure B was
chromatographed with chloroform–methanol mixtures
(100:1, 50:1 v/v) to give pure compound 23d (0.102 g,
52% yield) as a colorless oil. IR (film): m = 3282, 3086,
2982, 2935, 1786, 1757, 1220, 1028 cm-1; 1H NMR
(200 MHz, CDCl3): d = 8.83 (s, 1H), 8.26 (s, 1H), 7.69 (t,
J = 6.0 Hz, 1H, C(O)NHCH2), 4.96 (s, 2H, C(O)CH2),
4.29–4.10 (m, 4H, 2 9 POCH2CH3), 3.82 (d, J = 7.9 Hz,
2H, PCH2O), 3.70 (t, J = 4.6 Hz, 2H, PCH2OCH2CH2),
3.50 (t, J = 4.6 Hz, 2H, PCOCH2CH2), 1.43 (s, 18 H,
6 9 CH3), 1.35 (t, J = 7.1 Hz, 6H, 2 9 POCH2CH3) ppm;
13C NMR (151 MHz, CDCl3): d = 165.64, 153.53, 152.02,
150.43, 150.34, 145.63, 128.44, 83.72, 72.22 (d,
J = 8.8 Hz, PCOC), 65.59 (d, J = 166.8 Hz, PC), 62.69
(d, J = 6.7 Hz, POC), 46.07, 39.76, 27.79, 16.46 (d,
J = 5.5 Hz, POCC) ppm; 31P NMR (81 MHz, CDCl3):
d = 22.77 ppm.
Diethyl [2-(2-amino-6-chloro-9H-purin-9-yl)-
acetamido]methylphosphonate
(24a, C12H18ClN6O4P 9 0.5H2O)
The crude product obtained from 0.419 g diethyl
aminomethylphosphonate (7a, 2.51 mmol) and 0.571 g 2-
(2-amino-6-chloropurin-9-yl)acetic acid (16, 2.51 mmol)
in the presence of 0.481 g EDC 9 HCl (2.51 mmol) and
0.358 cm3 TEA (2.51 mmol) according to the general
procedure C was chromatographed with chloroform–
methanol mixtures (50:1, 20:1 v/v) and the selected
fractions were crystallized from a methanol–diethyl ether
mixture to give pure compound 24a (0.211 g, 22% yield)
as a white solid. M.p.: 130–132 C; IR (KBr): m = 3397,
3340, 3221, 3111, 3065, 2987, 2946, 1684, 1610, 1562,
1219, 1053, 1013 cm-1; 1H NMR (200 MHz, CD3OD):
d = 8.11 (s, 1H), 4.95 (d, J = 1.4 Hz, 2H, C(O)CH2),
4.21–4.10 (m, 4H, 2 9 POCH2CH3), 3.78 (d, J = 11.8 Hz,
2H, PCH2), 1.34 (t, J = 7.0 Hz, 3H, POCH2CH3) ppm;
13C
NMR (151 MHz, CD3OD): d = 167.18 (d, J = 3.5 Hz),
160.32, 154.18, 150.17, 143.84, 123.22, 62.80 (d,
J = 6.6 Hz, POC), 44.82, 34.37 (d, J = 158.6 Hz, PC),
15.26 (d, J = 6.0 Hz, POCC) ppm; 31P NMR (81 MHz,
CD3OD): d = 23.56 ppm.
Diethyl 2-[2-(2-amino-6-chloro-9H-purin-9-yl)-
acetamido]ethylphosphonate (24b, C13H20ClN6O4P)
The crude product obtained from 0.307 g diethyl 2-
aminoethylphosphonate (7b, 1.69 mmol) and 0.386 g 2-
(2-amino-6-chloropurin-9-yl)acetic acid (16, 1.69 mmol)
in the presence of 0.325 g EDC 9 HCl (1.69 mmol) and
0.236 cm3 TEA (1.69 mmol) according to the general
procedure C was chromatographed with chloroform–
methanol mixtures (50:1, 30:1, 10:1 v/v) and the selected
fractions were crystallized from a methanol–diethyl ether
mixture to give pure compound 24b (0.126 g, 19% yield)
as a white solid. M.p.: 158–160 C; IR (KBr): m = 3411,
3322, 3275, 3122, 3074, 2985, 2929, 1688, 1254,
1030 cm-1; 1H NMR (600 MHz, CD3OD): d = 8.05 (s,
1H), 4.84 (s, 2H, C(O)CH2), 4.13–4.09 (m, 4H,
2 9 POCH2CH3), 3.48-3.44 (m, 2H, PCH2CH2),
2.10–2.06 (m, 2H, 2H, PCH2), 1.32 (t, J = 7.0 Hz, 6H,
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2 9 POCH2CH3) ppm;
13C NMR (151 MHz, CD3OD):
d = 171.14, 164.26, 158.13, 154.12, 147.78, 127.21, 66.02
(d, J = 6.0 Hz, POC), 48.96, 37.43 (d, J = 1.7 Hz), 28.80
(d, J = 138.9 Hz, PC), 19.24 (d, J = 6.1 Hz, POCC) ppm;
31P NMR (243 MHz, CD3OD): d = 33.23 ppm.
Diethyl 3-[2-(2-amino-6-chloro-9H-purin-9-yl)-
acetamido]propylphosphonate (24c, C24H39N6O8P)
The crude product obtained from 0.203 g diethyl 3-
aminopropylphosphonate (7c, 1.04 mmol) and 0.237 g 2-
(2-amino-6-chloropurin-9-yl)acetic acid (16, 1.04 mmol)
in the presence of 0.199 g EDC 9 HCl (1.04 mmol) and
0.145 cm3 TEA (1.04 mmol) according to the general
procedure C was chromatographed with dichloromethane–
methanol mixtures (50:1, 20:1, 10:1 v/v) and the selected
fractions were crystallized from an ethanol–ethyl acetate
mixture to give pure compound 24c (0.106 g, 25% yield)
as a white solid. M.p.: 180–181 C; IR (KBr): m = 3408,
3343, 3273, 3090, 2988, 2945, 2908, 2869, 1680, 1644,
1608, 1215, 1040 cm-1; 1H NMR (600 MHz, CD3OD):
d = 8.07 (s, 1H), 4.87 (s, 2H, C(O)CH2), 4.15–4.06 (m,
4H, 2 9 POCH2CH3), 3.33 (t, J = 6.5 Hz, 2H, PCH2CH2-
CH2), 1.88–1.77 (m, 4H, PCH2CH2), 1.33 (t, J = 7.0 Hz,
6H, 2 9 POCH2CH3) ppm;
13C NMR (151 MHz, CD3-
OD): d = 167.34, 160.31, 154.19, 150.17, 143.87, 123.32,
61.90 (d, J = 6.7 Hz, POC), 45.15, 39.41 (d, J = 19.6 Hz,
PCCC), 26.61, 22.11 (d, J = 4.9 Hz, PCC), 21.98 (d,
J = 142.1 Hz, PC), 15.30 (d, J = 6.0 Hz, POCC) ppm; 31P
NMR (243 MHz, CD3OD): d = 32.75 ppm.
Diethyl 2-[2-(2-amino-6-chloro-9H-purin-9-yl)acetamido]-
ethoxy)methyl)phosphonate (24d, C14H22ClN6O5P)
The crude product obtained from 0.200 g diethyl (2-
aminoethoxy)methylphosphonate (7d, 0.947 mmol) and
0.216 g 2-(2-amino-6-chloropurin-9-yl)acetic acid (16,
0.947 mmol) in the presence of 0.182 g EDC 9 HCl
(0.947 mmol) and 0.132 cm3 TEA (0.947 mmol) accord-
ing to the general procedure C was chromatographed with
chloroform–methanol mixtures (50:1, 30:1 v/v) and the
selected fractions were crystallized from an ethyl acetate–
hexane mixture to give pure compound 24d (0.048 g, 15%
yield) as a white solid. M.p.: 91–93 C; IR (KBr):
m = 3430, 3335, 3220, 3095, 2981, 2938, 1650, 1611,
1245, 1024, 910 cm-1; 1H NMR (200 MHz, CD3OD):
d = 8.10 (s, 1H), 4.92 (s, 2H, C(O)CH2; superimposed in
the HOD signal), 4.28–4.13 (m, 4H, 2 9 POCH2CH3),
3.92 (d, J = 8.6 Hz, 2H, PCH2O), 3.70 (t, J = 5.3 Hz, 2H,
PCH2OCH2CH2), 3.47 (t, J = 5.3 Hz, 2H, PCOCH2CH2),
1.37 (t, J = 7.1 Hz, 6H, 2 9 POCH2CH3) ppm;
13C NMR
(151 MHz, CD3OD): d = 167.33, 160.30, 154.21, 150.14,
143.92, 123.25, 71.42 (d, J = 12.1 Hz, PCOC), 64.18 (d,
J = 167.6 Hz, PC), 62.77 (d, J = 6.6 Hz, POC), 44.96,
39.04, 15.36 (d, J = 5.5 Hz, POCC) ppm; 31P NMR
(81 MHz, CD3OD): d = 23.11 ppm.
Synthesis of the guanine derivatives 25a–25d (general
procedure)
A mixture of phosphonates 24a–24d (1.00 mmol) and
8 cm3 of a 75% aqueous trifluoroacetic acid was stirred at
room temperature for 48 h, concentrated in vacuo and co-
evaporated with water (3 9 5 cm3), ethanol (3 9 5 cm3),
and chloroform (3 9 5 cm3). The residue was crystallized
from the appropriate solvent.
Diethyl [2-(2-amino-1,6-dihydro-6-oxopurin-9-yl)ac-
etamido]methylphosphonate
(25a, C12H19N6O5P 9 2.5H2O)
From 0.112 g of compound 24a (0.297 mmol) the phos-
phonate 25a (0.087 g, 81%) was obtained as a white solid
after crystallization from a methanol–diethyl ether mixture.
M.p.: 165 C (decomposition); IR (KBr): m = 3425, 2988,
2928, 2854, 2732, 1697, 1214, 1026 cm-1; 1H NMR
(600 MHz, DMSO-d6): d = 10.63 (s, 1H, NH), 8.61 (t,
J = 5.9 Hz, 1H, C(O)NHCH2), 7.73 (s, 1H), 6.47 (s, 2H,
NH2), 4.72 (s, 2H, C(O)CH2), 4.06–3.98 (m, 4H,
2 9 POCH2CH3), 3.60 (dd, J = 11.8 Hz, J = 5.9 Hz,
2H, PCH2), 1.24 (t, J = 7.0 Hz, 6H, 2 9 POCH2CH3)
ppm; 13C NMR (151 MHz, DMSO-d6): d = 166.96 (d,
J = 4.5 Hz), 156.98, 154.22, 151.84, 138.76, 115.84,
62.35 (d, J = 6.0 Hz, POC), 45.24, 34.69 (d,
J = 154.0 Hz, PC), 16.70 (d, J = 6.0 Hz, POCC) ppm;
31P NMR (243 MHz, DMSO-d6): d = 22.46 ppm.
Diethyl 2-[2-(2-amino-1,6-dihydro-6-oxopurin-9-yl)ac-
etamido]ethylphosphonate (25b, C13H21N6O5P 9 H2O)
From 0.127 g of compound 24b (0.325 mmol) the phos-
phonate 25a (0.109 g, 90%) was obtained as a white solid
after crystallization from a methanol–diethyl ether mixture.
M.p.: 175 C (decomposition); IR (KBr): m = 3383, 2925,
2854, 1688, 1606, 1220, 1026 cm-1; 1H NMR (600 MHz,
DMSO-d6): d = 10.73 (s, 1H, NH), 8.35 (t, J = 5.5 Hz,
1H, C(O)NHCH2), 7.73 (s, 1H), 6.58 (s, 2H, NH2), 4.63 (s,
2H, C(O)CH2), 4.03–3.95 (m, 4H, 2 9 POCH2CH3), 3.30-
3.24 (m, 2H, PCH2CH2), 1.98–1.91 (m, 2H, 2H, PCH2),
1.24 (t, J = 7.0 Hz, 6H, 2 9 POCH2CH3) ppm;
13C NMR
(151 MHz, DMSO-d6): d = 166.78, 157.00, 154.31,
151.82, 138.68, 116.03, 61.62 (d, J = 4.5 Hz, POC),
45.45, 33.77, 25.72 (d, J = 136.2 Hz, PC), 16.71 (d,
J = 5.7 Hz, POCC) ppm; 31P NMR (81 MHz, DMSO-d6):
d = 30.12 ppm.
Diethyl 3-[2-(2-amino-1,6-dihydro-6-oxopurin-9-yl)ac-
etamido]propylphosphonate
(25c, C14H23N6O5P 9 2H2O)
From 0.050 g of compound 24c (0.12 mmol) the phospho-
nate 25c (0.042 g, 87%) was obtained as a white solid after
crystallization from a methanol–diethyl ether–petroleum
ether mixture. M.p.: 155 C (decomposition); IR (KBr):
m = 3385, 3277, 2928, 2864, 1689, 1609, 1228,
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1020 cm-1; 1H NMR (600 MHz, DMSO-d6): d = 10.91
(s, 1H, NH), 8.29 (t, J = 5.5 Hz, 1H, C(O)NHCH2), 8.06
(s, 1H), 6.68 (s, 2H, NH2), 4.70 (s, 2H, C(O)CH2), 4.04-
3.95 (m, 4H, 2 9 POCH2CH3), 3.33 (dd, J = 12.7 Hz,
J = 6.5 Hz, 2H, PCH2CH2CH2), 1.79–1.70 (m, 2H, PCH2-
CH2), 1.67–1.58 (m, 2H, PCH2CH2), 1.24 (t, J = 7.0 Hz,
6H, 2 9 POCH2CH3) ppm;
13C NMR (151 MHz, DMSO-
d6): d = 166.36, 156.24, 154.69, 151.53, 138.77, 113.98,
61.42 (d, J = 6.4 Hz, POC), 45.74, 39.62 (d, J = 18.3 Hz,
PCCC), 22.80 (d, J = 4.5 Hz, PCC), 22.65 (d,
J = 140.4 Hz, PC), 16.74 (d, J = 4.5 Hz, POCC) ppm;
31P NMR (243 MHz, DMSO-d6): d = 31.64 ppm.
Diethyl 2-[2-(2-amino-1,6-dihydro-6-oxopurin-9-yl)ac-
etamido]ethoxy)methyl)phosphonate
(25d, C14H23N6O6P 9 H2O)
From 0.012 g of compound 24d (0.029 mmol) the phos-
phonate 25d (0.010 g, 83%) was obtained as a yellowish
oil. IR (film): m = 3378, 3288, 2938, 2881, 1690, 1611,
1225, 1018 cm-1; 1H NMR (600 MHz, DMSO-d6):
d = 10.64 (s, 1H), 8.28 (t, J = 5.6 Hz, 1H), 7.80 (brs,
1H), 6.50 (s, 2H), 4.66 (s, 2H, C(O)CH2), 4.08–4.03 (m,
4H, 2 9 POCH2CH3), 3.83 (d, J = 8.0 Hz, 2H, PCH2O),
3.56 (t, J = 5.7 Hz, 2H, PCH2OCH2CH2), 3.27 (q,
J = 5.7 Hz, 2H, PCOCH2CH2), 1.25 (t, J = 7.0 Hz, 6H,
2 9 POCH2CH3) ppm;
13C NMR (151 MHz, DMSO-d6):
d = 166.87, 156.96, 154.28, 150.14, 138.78, 115.52, 71.44
(d, J = 11.0 Hz, PCOC), 64.50 (d, J = 162.9 Hz, PC),
62.23 (d, J = 6.3 Hz, POC), 45.44, 39.02, 16.75 (d,
J = 5.2 Hz, POCC) ppm; 31P NMR (243 MHz, DMSO-
d6): d = 21.45 ppm.
Antiviral activity assays
The compounds were evaluated against the following
viruses: herpes simplex virus type 1 (HSV-1) strain KOS,
herpes simplex virus-2 strain G, thymidine kinase-deficient
(TK-) HSV-1 KOS strain resistant to ACV (ACVr), ade-
novirus-2, vesicular stomatitis virus, varicella-zoster virus
(VZV) strain Oka, TK- VZV strain 07-1, human cytome-
galovirus (HCMV) strains AD-169 and Davis, feline herpes
virus (FHV), vaccinia virus Lederle strain, respiratory
syncytial virus (RSV) strain Long, vesicular stomatitis
virus (VSV), feline coronovirus (FIPV), Coxsackie B4,
Parainfluenza 3, Influenza virus A (subtypes H1N1, H3N2),
influenza virus B, Reovirus-1, Sindbis, Reovirus-1, Punta
Toro, yellow fever virus. The antiviral, other than anti-
HIV, assays were based on inhibition of virus-induced
cytopathicity or plaque formation in human embryonic
lung (HEL) fibroblasts, African green monkey cells (Vero),
human epithelial cells (HeLa), Crandell–Rees feline kidney
cells (CRFK) or Madin–Darby canine kidney cells
(MDCK). Confluent cell cultures in microtiter 96-well
plates were inoculated with 100 CCID50 of virus (1 CCID50
being the virus dose to infect 50% of the cell cultures) or
with 20 plaque forming units (PFU) (VZV) in the presence
of varying concentrations of the test compounds. Viral
cytopathicity or plaque formation was recorded as soon as
it reached completion in the control virus-infected cell
cultures that were not treated with the test compounds.
Antiviral activity was expressed as the EC50 or compound
concentration required to reduce virus-induced
cytopathogenicity or viral plaque formation by 50%.
Cytotoxicity of the test compounds was expressed as the
minimum cytotoxic concentration (MCC) or the compound
concentration that caused a microscopically detectable al-
teration of cell morphology.
Cytostatic activity assays
All assays were performed in 96-well microtiter plates. To
each well were added (5–7.5) 9 104 tumor cells and a
given amount of the test compound. The cells were allowed
to proliferate for 48 h (murine leukemia L1210 cells) or
72 h (human lymphocytic CEM and human cervix carci-
noma HeLa cells) at 37 C in a humidified CO2-controlled
atmosphere. At the end of the incubation period, the cells
were counted in a Coulter counter. The IC50 (50% inhibi-
tory concentration) was defined as the concentration of the
compound that inhibited cell proliferation by 50%.
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